Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMG5C8D)

Drug Name
GS-9620 Drug Info
Synonyms
GS-9620; 1228585-88-3; Vesatolimod; GS9620; UNII-O8M467C50G; GS 9620; CHEMBL2424780; O8M467C50G; 8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one; 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; 4-Amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one; 4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; Vesatolimod [INN]; Vesatolimod [USAN:INN]; Vesatolimod (USAN/INN); SCHEMBL10083191
Indication
Disease Entry ICD 11 Status REF
Hepatitis B virus infection 1E51.0 Phase 2 [1]
Human immunodeficiency virus infection 1C62 Phase 1 [2]
Cross-matching ID
PubChem CID
46241268
CAS Number
CAS 1228585-88-3
TTD Drug ID
DMG5C8D
INTEDE Drug ID
DR1834

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Phase 2 [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Toll-like receptor 7 (TLR7) DTT TLR7 3.7 0.848 -0.152 3.121
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatitis B virus infection
ICD Disease Classification 1E51.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 7 (TLR7) DTT TLR7 3.32E-25 0.44 0.88
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.29E-36 -3.75E-01 -1.06E+00
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320-8.